The acquisition will bring the Nasdaq-listed Theratechnologies back under privat...
The UK’s Labour Government has revealed its ’10-year plan’ for the country’s Nat...
BioVersys and Shionogi have entered a research and exclusive licence option agre...
Lynozyfic has the potential to be administered monthly, giving it an advantage o...
Data fragmentation slows operations, increases costs, and blocks the ability to ...
Modella AI has signed a multi-year agreement with AstraZeneca for expediting AI-...
The approval comes amid speculation that AstraZeneca CEO Pascal Soriot is consid...
More than half of the top 15 pharma companies are expected to face challenges in...
Biocon Biologics’ Denosumab biosimilars, Vevzuo and Evfraxy, have received marke...
Brii Biosciences and Joincare Pharmaceutical have signed a licence and technolog...
Merck KGaA has concluded the previously announced acquisition of SpringWorks The...
By 2030, the cell and gene therapy market is projected to be worth £76.03bn, and...
Life science professionals must navigate a complex regulatory maze to implement ...
A new podcast from industry experts MarketScan explains why social determinants ...
Dizal has received FDA approval for Zegfrovy to treat adults with locally advanc...
The UK Government is pushing for a single, unified digital patient record within...
